(Q43158828)

English

Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06).

scientific article published on 15 February 2010

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Activity of a multitargeted chemo-switch regimen (sorafenib, gemcitabine, and metronomic capecitabine) in metastatic renal-cell carcinoma: a phase 2 study (SOGUG-02-06). (English)

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

1 reference

based on heuristic

inferred from title

Joan Carles Galcerán

4

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

José Luis Pérez-Gracia

5

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

author name string

Joaquim Bellmunt

1

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

José Manuel Trigo

2

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Emiliano Calvo

3

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Jordi Rubió

6

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Juan Antonio Virizuela

7

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Rafael López

8

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Martín Lázaro

9

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Joan Albanell

10

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

publication date

15 February 2010

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Lancet Oncology Commission

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

11

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

350-357

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970383-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970383-3

7 January 2021

based on heuristic

inferred from DOI database lookup

The anti-angiogenic basis of metronomic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970383-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970383-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970383-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970383-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer: antitumor activity and correlation with vascular endothelial growth factor levels

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970383-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Metronomic antiangiogenic therapy with capecitabine and celecoxib in advanced tumor patients--results of a phase II study.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970383-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970383-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970383-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970383-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A multitargeted, metronomic, and maximum-tolerated dose "chemo-switch" regimen is antiangiogenic, producing objective responses and survival benefit in a mouse model of cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970383-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II study of gemcitabine and capecitabine in metastatic renal cancer: a report of Cancer and Leukemia Group B protocol 90008

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970383-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase II clinical trial of capecitabine and gemcitabine chemotherapy in patients with metastatic renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970383-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase II trial of gemcitabine plus capecitabine for metastatic renal cell cancer previously treated with immunotherapy and targeted agents

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970383-3

7 January 2021

based on heuristic

inferred from DOI database lookup

A phase ii study of gemcitabine and capecitabine in patients with advanced renal cell cancer: Southwest Oncology Group Study S0312

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970383-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Capecitabine in the treatment of metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970383-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Prognostic factors for survival in previously treated patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970383-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Bevacizumab combined with gemcitabine and capecitabine for advanced pancreatic cancer: a phase II study

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970383-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Phase I trial of sorafenib and gemcitabine in advanced solid tumors with an expanded cohort in advanced pancreatic cancer

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970383-3

7 January 2021

based on heuristic

inferred from DOI database lookup

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970383-3

7 January 2021

based on heuristic

inferred from DOI database lookup

One-sample multiple testing procedure for phase II clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970383-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970383-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Metronomic low-dose oral cyclophosphamide and methotrexate plus or minus thalidomide in metastatic breast cancer: antitumor activity and biological effects.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970383-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Metronomic cyclophosphamide and capecitabine combined with bevacizumab in advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970383-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Pilot study of DCE-MRI to predict progression-free survival with sorafenib therapy in renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970383-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Dynamic contrast-enhanced magnetic resonance imaging pharmacodynamic biomarker study of sorafenib in metastatic renal carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970383-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Active chemotherapy for sarcomatoid and rapidly progressing renal cell carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970383-3

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(09)70383-3

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

15 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43158828&oldid=2166847441"